We’re sharing Phase 3 results evaluating our investigational oral macrocyclic peptide. These results from our third pivotal Phase 3 study underscore our commitment to advancing science with the goal of helping patients. Learn more: https://go.msd.com/~lx0
About us
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.
- Website
-
http://www.msd.com
External link for MSD
- Industry
- Pharmaceutical Manufacturing
- Company size
- 10,001+ employees
- Headquarters
- Rahway, New Jersey
- Type
- Public Company
Locations
Employees at MSD
Updates
-
Innovation in cardio-pulmonary diseases, including different types of pulmonary hypertension, continues to be a top research priority for our pipeline. At our company, we follow the science and are committed to making a difference for patients around the world. Learn more: https://go.msd.com/~mb8
-
About 24% of adults worldwide have hypercholesterolemia — or high cholesterol. High bad cholesterol (LDL-C) is a major risk factor for heart attack or stroke. That’s why we continue to advance research to help combat the cardiovascular (CV) epidemic and help address the burden it places on patients. Learn more: https://go.msd.com/~u5x
-
Building on a nearly 70-year history in cardiovascular (CV) disease research, our focus includes highly prevalent as well as uncommon diseases that affect the heart and lungs. We’re committed to advancing research for patients impacted by cardio-pulmonary diseases. Learn more: https://go.msd.com/~mb8
-
Today, we announced an agreement to acquire Terns Pharmaceuticals, a clinical-stage #oncology company, building on our growing presence in hematology with a potential best-in-class candidate for the treatment of certain patients with chronic myeloid #leukemia (#CML). Read more about how this acquisition supports our science-led, value-enhancing business development strategy: go.msd.com/~dpo9lg
-
We’re on a mission to break down the barriers that stand in the way of lung cancer screening and early detection. Explore how we are doing this through our initiative, Mission Lung Cancer: https://go.msd.com/~7nm
-
Our goal is to enable early detection of lung cancer to help ensure patients get timely care. Learn more about our efforts through our Mission Lung Cancer initiative: https://go.msd.com/~7nm
-
Smartwatches and other wearables aren’t just for fitness, they’re helping reshape clinical research. In #ScientistontheStreet, host Andrew Latham joins Marissa Dockendorf and our digital clinical measures team to see how they’re exploring the use of data—from timed walk tests to passive sleep monitoring—to capture objective measures of health and treatment response outside the clinic. This helps deepen disease understanding and can support more efficient and patient-centric drug development. Learn more: https://go.msd.com/~7vh